# Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

> **NCT02070458** · PHASE1 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Adult Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia

## Interventions

- **DRUG:** ixazomib
- **DRUG:** mitoxantrone hydrochloride
- **DRUG:** etoposide
- **DRUG:** cytarabine

## Key facts

- **NCT ID:** NCT02070458
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-08
- **Primary completion:** 2017-03-17
- **Final completion:** 2017-08-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02070458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02070458, "Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02070458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*